Blood cell medicine for early liver failure
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether giving a medicine that helps the body make more blood cells (called GCSF and darbepoetin) either once or a few times can help people with early liver failure (decompensated cirrhosis). The goal is to see if it helps the liver work better and improve the patient's health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage decompensated cirrhosis, meaning your liver is damaged and it is no longer able to do its job fully, but it is not the most severe stage.
- Your liver disease is NOT caused by a virus like hepatitis B or C.
- You do not have severe swelling of the abdomen (called ascites) or the most severe form of liver disease (Child C).
- You have not had a variceal bleed (bleeding from the veins in your esophagus) in the last 3 months.
- You do NOT have liver cancer, other cancers, kidney failure, serious infections, or other major health conditions.
- You are between 18 and 65 years old and not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental liver cell injection to see if it is safe and can help people with decompensated cirrhosis, a serious liver condition. If you qualify, you may receive this new treatment to potentially improve liver function.
This trial tests umbilical-cord stem cells to see if they can improve outcomes in people with decompensated (worsening) cirrhosis. You may be considered if your liver disease is moderate to severe (MELD 15–30) and you do not have certain high-risk problems right now.
This trial tests a new cell injection called HCL001 for people with decompensated cirrhosis (advanced liver scarring causing complications). The goal is to see if it's safe and helps improve liver function. It may be an option if you've tried standard treatments and meet specific health criteria.
This study tests whether a combination of two medicines (G-CSF and darbepoetin) given in one or more cycles can improve the body's immune and metabolic health in people with early-stage decompensated cirrhosis (advanced liver disease with mild complications). It compares these treatments with standard medical care.
This study tests whether a special type of stem cell therapy (called mesenchymal stem cells) can help people with a severe liver condition called acute-on-chronic liver failure (ACLF). The goal is to see if this treatment can improve liver function and reduce the need for a liver transplant.
This trial tests whether a treatment called plasma exchange (which removes harmful substances from your blood and replaces them with healthy plasma) can help improve the function of other organs, like the kidneys or lungs, in people with advanced liver failure. It aims to find out if this treatment helps you recover better and to identify markers that show if the treatment is working.
Hear when a new Decompensated Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.